Isofol Medical reported the results from the second quarter of 2018 earlier this morning. The Q2 report contained several important updates on progression in the research portfolio. We expect to see rising activity in the second half of 2018, where the most significant potential catalysts are top-line data from the ongoing CC-005 trial and feedback on the updated SPA application from FDA.